Results 121 to 130 of about 64,783 (272)

Pyroptosis in Preeclampsia: Placenta‐to‐Maternal Organ Communication, Molecular Mechanisms, and Therapeutic Targets

Comprehensive Physiology, Volume 16, Issue 6, December 2026.
Schematic diagram illustrating the potential mechanisms and core molecules contributing to the development of PE via mediating pyroptosis: focus on trophoblasts and endothelial cells. Pyroptosis of trophoblast cells in the placenta of preeclampsia not only inhibits its invasion, migration, and differentiation, causing local infiltration and ...
Xianyi Zhou, Liming Yuan, Ya Li, Rong Zhou, Linbo Gao, Xiaohong Wei   +5 more
wiley   +1 more source

Ceftriaxone‐induced liver injury: Incidence, phenotypic characterization and predictive factors

British Journal of Clinical Pharmacology, Volume 92, Issue 11, Page 3874-3885, November 2026.
Introduction Ceftriaxone is a widely used third‐generation cephalosporin in hospitalized patients. Although generally considered safe, it has been associated with hepatobiliary complications and emerging reports of drug‐induced liver injury (DILI). However, data on its true incidence, phenotypic patterns, and predictors remain limited. This study aimed
Mohamed Hatem, Mohannad N. AbuHaweeleh, Humam Emad Rajha, Mhd Osama Rahhal, Ahmad Hamdan, Lina Naseralallah   +5 more
wiley   +1 more source

Should TNF inhibitors be avoided in psoriasis patients with latent tuberculosis?

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Fabià Torres‐Betato, Lluís Puig
wiley   +1 more source

Pharmacogenomics of dolutegravir: A scoping review of evidence, gaps and clinical implications

British Journal of Clinical Pharmacology, Volume 92, Issue 11, Page 3716-3732, November 2026.
Dolutegravir underpins modern first‐ and second‐line HIV treatment regimens; however, interindividual variability in its disposition and tolerability presents challenges for optimal use. This scoping review mapped current evidence on the pharmacogenomics of dolutegravir, focusing on pharmacokinetics and pharmacodynamics, and methodological limitations ...
Ronald Kiguba, Mishael Ssesanga, Munir Pirmohamed   +2 more
wiley   +1 more source

Successful Translational Prediction of Bedaquiline's Phase 2a Clinical Trial Results against Tuberculosis: The Zebrafish as a New Approach Methodology

Clinical Pharmacology &Therapeutics, Volume 120, Issue 5, Page 1281-1286, November 2026.
Tuberculosis remains an urgent global health crisis that requires an accelerated development of novel regimens. Rodent and rabbit studies currently inform early translational predictions. However, the zebrafish (Danio rerio) embryo/larva, as a New Approach Methodology, provides an ethical, cost‐effective, and high‐throughput non‐mammalian disease model
Bart van Lieshout, Aanisah Hanuun, J. G. Coen van Hasselt, Rob C. van Wijk   +3 more
wiley   +1 more source

Short Term Effects of Football Headers on Reaction Time and Symptomology in Males and Females

European Journal of Sport Science, Volume 26, Issue 11, November 2026.
ABSTRACT Introduction Football heading is a form of repetitive head impact linked to cognitive decline. Although the English Football‐Association have implemented heading restrictions, evidence guiding sex‐specific protocols remains limited. This study explored the acute effects of a standardized heading drill on reaction time (RT) and concussion ...
Yusef Mohammed, Rithik Rajan, Benjamin Tari, Flaminia Ronca   +3 more
wiley   +1 more source

Beyond Pigmentation: Interplay of Metabolic Profile, Carotid Intima—Media Thickness, and Fatty Liver in Vitiligo: An Age‐ and Sex‐Matched Case‐Control Study

Health Science Reports, Volume 9, Issue 11, November 2026.
ABSTRACT Background and Aims Vitiligo shares inflammatory and metabolic pathways with cardiovascular and hepatic steatosis. Carotid intima–media thickness (IMT) is an established marker of early subclinical atherosclerosis, whereas non‐alcoholic fatty liver disease (NAFLD) reflects hepatic involvement in chronic inflammatory and metabolic dysregulation.
Mehrdad Mozafar, Yasamin Bigdeli, Mehdi Azizmohammad Looha, Reza Samiee, Safoura Shakoei, Ifa Etesami, Zeinab Aryanian, Faezeh Khorasanizadeh, Parvaneh Hatami   +8 more
wiley   +1 more source

Response to treatment with isoniazid plus PAS of tuberculous patients with primary isoniazid resistance

, 1969
The response to treatment with isoniazid plus PAS was studied in 30 patients with primary isoniazid resistance and 459 patients with initially isoniazid-sensitive cultures.
Stott, H, Tripathy, S P, Menon, N K, Narayana, A S L, Somasundaram, P R, Mitchison, D A, Velu, S   +6 more
core   +1 more source

Prescription Intervals of Medications for Chronic Use: A Cohort Study

Pharmacoepidemiology and Drug Safety, Volume 35, Issue 11, November 2026.
ABSTRACT Purpose In deprescribing studies, a prescription‐free gap is typically used to determine if patients discontinued their treatment. An appropriate gap depends on the typical time between prescriptions during continued use. This work aims to characterise the interval between prescriptions of chronic drugs (long‐term use) using different methods ...
Ryan Muddiman, Padraic Donoghue, Jessica Gómez Lemus, Ann Sinéad Doherty, Fiona Boland, Caroline McCarthy, Frank Moriarty   +6 more
wiley   +1 more source

The Blind Spot of GeneXpert MTB/RIF: Isoniazid‐Resistant, Rifampicin‐Susceptible Tuberculosis Detected on Phenotypic Drug Susceptibility Testing

Respirology Case Reports, Volume 14, Issue 11, November 2026.
GeneXpert MTB/RIF reports only rifampicin resistance, so a result of ‘rifampicin resistance not detected’ does not exclude isoniazid resistance. In this young man with hemoptysis and bilateral infiltrates, phenotypic drug susceptibility testing of bronchoalveolar lavage revealed isoniazid‐resistant, rifampicin‐susceptible tuberculosis after 1 month of ...
Hafiz Muhammad Faisal Nadeem, Ali Gohar, Muhammad Faisal Jakhar, Rabbia Abbas, Taqdees Noor, Muhammad Husnain Ahmad   +5 more
wiley   +1 more source